# Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

> **NCT06544733** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 675 (estimated)

## Conditions studied

- HIV-1-Infection

## Interventions

- **DRUG:** Lepetegravir
- **DRUG:** Lenacapavir pacfosacil
- **DRUG:** Placebo to Match BVY
- **DRUG:** Bictegravir/emtricitabine/tenofovir alafenamide
- **DRUG:** Lepetegravir/Lenacapavir pacfosacil FDC
- **DRUG:** Placebo to Match GS1720/GS-4182 FDC

## Key facts

- **NCT ID:** NCT06544733
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-20
- **Primary completion:** 2028-01
- **Final completion:** 2029-06
- **Target enrollment:** 675 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544733, "Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06544733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*